The association between periodontitis and the impact of oral health on the quality of life of individuals with psoriasis and psoriatic arthritis

Introduction

The term periodontal diseases encompass changes that affect periodontal tissues which protect and insert the teeth, such as gingivitis and periodontitis (PE). PE is characterized by host-mediated, microbiologically associated inflammation, resulting in loss of periodontal attachment(1). Susceptibility to PE is related to polymicrobial disorders that result in dysbiosis considering its complex pathogenesis. The precise mechanisms that lead to the onset of PE are not completely known yet, although studies have shown that PE onset and progression depend on an imbalance in the individual’s immunoinflammatory response to dental biofilm microorganisms. Since the presence of biofilm is essential but not sufficient for PE onset, the recognition of microbial components by defense cells and the production of inflammatory mediators is indeed crucial(2). This recognition can activate the acquired immune response, leading to the differentiation of T-helper cells (Th) into Th1, Th2, Th17 or T-regulatory cells (Treg)(3). Th1 and Th2 cells of the adaptive immune system are the main agents in the pathogenesis of immune-mediated diseases. Th17 cells and the cytokines IL-17 and IL-23 seem to play fundamental roles(3).

Since the American Academy of Periodontology (1999) workshop considerable evidence has emerged regarding potential effects of PE on systemic diseases such as endocrine, cardiac, autoimmune disorders and adverse pregnancy outcomes(4–6).

Psoriasis (PSO) is a chronic inflammatory skin disease characterized by the inflammation of the dermis and epidermis. Its prevalence varies due to country-specific variations and the methodological variability of epidemiological studies, but in a global analysis, it has been outlined to vary from 0.14% to almost 3%. Given the growing and the aging of worldwide population and the fact that PSO primarily affects the adults, the burden associated with PSO may continue to increase(7). Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease that has been defined as an inflammatory arthritis associated with PSO and seronegative for rheumatoid factor. PsA occurs in 2-3% of the general population, but among patients with PSO the prevalence varies from 6% to 42%, with involvement of the skin, nails, bones, tendons, ligaments, synovial membrane and joints(8,9).

Increasing evidence supports the association between PSO, PsA and multiple comorbidities including obesity, metabolic syndrome, cardiovascular disease, cerebrovascular disease, anxiety and depression (10,11) and PE (6,12–15).

The hypothesis of an association between these diseases is that PE can play a direct and indirect role in the development or exacerbation of psoriatic disease, as both consist of a complex interrelationship between cell types of the innate and acquired immune system, immunological factors produced by T cells, dendritic and Th1-mediated cells, through the IL-23/IL-17 axis and because they share some risk factors (e.g., diabetes and smoking) (16,17).

The relationship between PE, PSO and especially PsA has gaps and the pathophysiological paths of this association are not completely elucidated. To date, only 4 studies have been reported on the association of PE and PsA. (12–14,18) Hence, literature is significantly scarce in relation to studies that address the impact of OHRQoL of individuals with psoriatic disease.

This study is then justified by the need for greater knowledge about the potential association between PSO, PsA and PE, and the similarities in their comorbidities and risk factors, and also to seek a greater understanding of OHRQoL of the affected individuals. Thus, we hypothesized that higher OIPD scores are associated with the presence of worse periodontal clinical conditions in individuals with psoriatic disease.

The aim of this case-control study was to evaluate periodontal status, its clinical and epidemiological aspects and the impact of OHRQoL in PSO and PsA individuals compared to those without psoriatic disease.

Materials and Methods

Results

The sample consisted of 210 psoriasis individuals (PSO), 86 with PsA and 359 controls, 407 women and 248 men, with a mean age of 47.5 (±5.1) years for the control group, 49.7 (±4.2) years for the PSO group (p<0.001); and 48.8 (± 4.3) for the PsA group (p= 0.011) (Table 1). Regarding variables of interest, PSO individuals presented significantly higher values of the occurrence of diabetes (p=0.004), alcohol consumption (p=0.001), antidepressants (p=0.006) and anxiolytics (p = 0.008), as well as higher BMI (p <0.001) (Table 1) when compared to controls. PsA individuals also showed greater antidepressants (p<0.001) and anxiolytics use (p=0.013), diabetes (p=0.002) and higher BMI (p<0.001) compared to controls. In addition, data demonstrated PsA individuals had greater alcohol (p=0.040) and antidepressants (p=0.036) consumption than PSO individuals.

Table 2 shows the comparison between groups regarding periodontal parameters. PsA individuals showed significantly more PE (57.0%; OR=2.67, 95%CI: 1.65-4.32 p<0.001), while PSO (34.3%; OR=1.05; 0.73-1.51; p<0.001) than controls. PsA and PSO group revealed a greater number of sites and teeth with PD 4-6mm than controls (p<0.001). PD mean in PsA was significantly higher than in PSO (p=0.004) and controls (p=0.001), as well as in the comparison between PSO and controls (p<0.001). CAL frequency of >6mm was higher in PsA group, and significantly higher than in PSO group (p<0.001) and controls (p=0.001). Regarding BOP, higher mean values were observed in PsA, followed by PSO and controls (PsA>PSO>Controls; p<0.001) and (PSO>controls; p=0.034)]. As for IP; PsA group presented significantly higher and worse scores than those reported in the PSO group (p=0.001) and controls (p<0.001).

When analyzing OHRQoL, PsA group presented a significantly higher mean impact (p= 0.011) than controls (Supplementary Figure 1). Interestingly, when using the OIDP stratification into no impact (0), low (1–15), medium (16–45) and high (45–200) scores a significant difference was identified among PSO and PsA individuals, who have a higher mean of high OIDP scores when compared to controls (p<0.001). High OIDP scores indicate worse OHRQoL.

• Download figure
• Open in new tab

Supporting Figure 1. Stratification of OIDP scores between groups

Table 3 shows the characterization of individuals regarding each OIDP activity, in frequency and severity. A significant difference exists when there is no overlap between CI as in the comparison of the frequency of discomfort when speaking between patients with and without PE in the control group: those with PE experienced discomfort when speaking more frequently than those without PE. It is observed that in the control and PSO groups, 11 items do not overlap, indicating a significant difference between them, and that they are worse in the presence of PE. In the PsA group, the situation is reversed and 11 items overlap. This result may suggest that PsA disease is more debilitating and has a greater impact on the individual’s overall QoL, so that they feel and report less discomfort in the presence of PE or even worry less about their oral condition.

When evaluating the influence of variables of interest on QoL in a dichotomous manner (without/with impact), Table 4 shows that alcohol and anxiolytics use, presence of periodontitis, and psoriasis with periodontitis were significant (p<0.001). In the final logistic regression model, PE (p<0.001) and alcohol/anxiolytic use (p=0.002) remained significantly (Table 5).

Regarding periodontal parameters influence on QoL (Table 6), a significant difference was observed for the presence of PE; PD > 6mm; CAL >6mm (p<0.001); higher plaque index (p=0.002), higher BOP % of sites (p=0.005) and teeth (p=0.006). There was a higher PD<3mm (41.6%) percentage of sites in individuals without impact and sites with PD>6mm in individuals with impact (3.1%) (p<0.001). Also, higher PD>6mm % of teeth (8.1% - p<0.001) in individuals with impact, with the same occurring for CAL > 6mm [% of sites (8.4%) and teeth (14.5%) - (p <0.001)]. These data demonstrated that a worse clinical periodontal condition had a negative impact on the analyzed individuals’ OHRQo (Table 6).

Discussion

The present study demonstrated a risk association between PSO and PE, with PsA individuals having significantly worse OHRQoL indicators. A significantly higher PE prevalence was observed among PsA individuals (57%) when compared to controls (33.1%). In PSO (34.35%), the comparison was not significant despite the higher prevalence. PsA individuals had a 2.67 greater chance of developing PE than controls (OR =2.67; p<0.001). Additionally, they presented a significantly worse periodontal clinical condition, expressed by higher means of PI, BOP, PD, CAL as well as % of sites with PD 3-6 mm and >6 mm.

A high prevalence of PE in psoriatic disease individuals is reported in several studies,(12–14,19,28–30) most of which addressed PSO. The literature does not always categorize PSO and PsA conditions separately. Most studies address PSO and some encompass PsA, (12–14,18) referring to these two categories of disease uniquely in their discussion, using terms such as “psoriatic disease” or even “psoriasis group”. This fact directly impacts the possibility of better understanding the prevalence of PE, specifically in PsA. However, within the available literature, when separately evaluating PSO and PsA, the high prevalence of PE in our study (57%) in PsA is very similar to the literature, as reported in the recent study by Mishra et al. (13) [(PsA (58.18%) vs. control (42.72 – p=0.042)]. Due to this gap in the literature, it is of high relevance that new studies should aim at individuals with PsA to better elucidate whether their possible greater immune vulnerability puts them at greater risk for PE, credited to the fact of greater severity of psoriatic disease.

Regarding the worse periodontal condition of PSO individuals, our findings corroborate other recent and robust studies reported (12,14,19,28). Our definition of “robust” was based on full-mouth examinations, significant samples and well-defined criteria for PE and psoriatic disease, bringing greater reliability to the findings.

A possible association between PE and increased risk of immune-mediated inflammatory diseases has been increasingly recognized. Although the biological mechanism that explains the increased risk of psoriatic disease among individuals with PE is unknown, several hypotheses have been proposed. One is related to its shared pathology, since exaggerated immune responses to the microbiota present on the epithelial surface are observed in both conditions, suggesting a genetic predisposition that affects dendritic cells and the expression of toll-like receptors (9,16,31,32). Therefore, these pathologies (PE, PsA and PSO) are immune-mediated and present similar etiopathogenic pathways, involving greater susceptibility of an individual with an immune response deficiency and common risk factors.

Observational studies have also confirmed findings of the association between PE and psoriatic disease (12,18,19). However, it is worth mentioning some limitations of these studies, such as: (i) use of retrospective data obtained from medical records(12,14); (ii) use of periodontal indexes to define PE(18,28,29); (iii) small samples(18,28,29); (iv) self-reported information on periodontal conditions and PSO(29,33) and (v) causality bias, as the diseases share numerous risk factors (e.g. smoking and diabetes) (6,15). To date, these limitations may together be an important factor in the presence of conflicting results and moderate evidence for an association between these diseases.

This study demonstrated that individuals with PSO and PsA showed significantly higher BMI values, anxiolytics/antidepressants use and occurrence of diabetes than controls. Those with PSO had greater alcohol consumption than controls (p=0.001), and those with PsA had greater alcohol (p=0.040) and antidepressants (p=0.036) use than PSO individuals. These data corroborate previous findings, since these variables can contribute to systemic triggers activation leading to immunological changes (exacerbation in the expression of cytokines), endocrine and behavioral disorders (lack of hygiene, smoking and other harmful habits) which can predispose greater susceptibility to these diseases (4).

It is noteworthy that mood disorders (particularly depression) have been suggested to be significantly more prevalent in PSO individuals (up to 62%) than in the general population (4 to 10%)(10). Other mental health comorbidities such as anxiety and suicidal ideation have been reported to be more prevalent in psoriatic disease individuals (34).

Contributing factors for this higher prevalence have been reported as: (1) the disease physical impact, with compromised dermal integrity and symptoms such as pain, itching, joint stiffness (35); (2) the clinical signs of the disease, such as skin disfigurement, negatively and directly impacting self-perception of one’s own body (35) and (3) psychiatric disorders that may result in and contribute to the progression of psoriatic disease, suggesting that psoriatic disease and psychiatric conditions (e.g. depression) may have overlapping biological mechanisms – explained by an inflammatory model (10,34).

Several studies have reported that PSO strongly influences global QoL of psoriatic individuals(36–38) and a recent systematic review indicates a higher prevalence of depression and anxiety in PsA, demonstrating worse QoL of these individuals(39).

As evidence suggests that psoriatic patients have worse oral conditions and worse periodontal parameters, it can be assumed that the QoL of these individuals is even more negatively affected by oral changes. Literature already corroborates to the fact that oral conditions such as pain, cavities, tooth mobility and tooth loss, have negative effects on the well-being of individuals, especially in those with PE (38,40).

However, this is the first study that addresses OHRQoL in PsA individuals to date, particularly targeting periodontal condition. Only one recent study(41) evaluated OHRQoL in PSO. The authors reported a risk association between PSO and PE, with individuals with both diseases having significantly worse OHRQoL indicators. In addition, PE and PSO severity significantly increased these negative effects.

The hypothesis proposed in the study that individuals with PsA and PE would present worse OHRQoL indicators was confirmed. Results demonstrated that PsA group had significantly higher mean impact on OHRQoL (p= 0.011) than the controls. A significant difference was identified among PsA and PSO individuals, who had higher means of high OIDP scores when compared to controls (p<0.001). High OIDP scores indicate worse QoL. These data reinforce the existing, albeit scarce, literature on the impact of psoriatic disease on OHRQoL (38,41).

A higher percentage of individuals with an impact on QoL was observed in those with PE (45.8%) when compared to those without PE (28.7%) when evaluating QoL and periodontal parameters Thus, our findings corroborate those of negative impacts of PE on OHRQoL, reinforcing the literature that points out that worse periodontal conditions negatively and significantly affect individuals’ routine activities. Literature reports studies using the OIDP to assess OHRQoL (40–43) while others used different instruments, such as the Oral Health Impact Profile questionnaire (OHIP-14) (44,45).

Some limitations must be attributed to the present study. The main one being inherent to a case-control study which does not demonstrate a causal link due to temporality; with our data, it is not possible to determine whether PE led to greater susceptibility to psoriatic disease or whether individuals with psoriatic disease develop more PE. Patient-reported outcomes (PROMs) such as the questionnaire application in an interview form may have potential interviewer bias, however the extensive impact grading [from 0 (null) to 5 (maximum)] tends to minimize this effect.

On the other hand, advantages can also be cited as (i) high number of individuals in the sample, increasing the statistical power of the study, since PSO has a low prevalence, making it difficult to obtain large samples; (ii) PSO and PsA diagnosis by specialized physicians; (iii) full mouth periodontal examination with robust criteria for PE definition, as it is recognized that the quality of periodontal data and the criteria for defining PE strongly impacts the results of association studies(46); and (iv) uniform methodology for clinical assessment and questionnaire application. However, we highlight the need for additional studies in different populations, with different study designs to expand our knowledge on OHRQoL in psoriatic disease patients.

Thus, our study can be considered an important starting point for investigations into OHRQoL PsA patients and the association between PE and psoriatic disease, highlighting the inclusion of PE as another important comorbidity associated mainly with PsA. Also, the need for attention to the oral condition and its impacts of OHRQoL by both dentists and doctors of these individuals who already present greater physical-emotional vulnerability is advised.

Periodontists and dermatologists must broaden their clinical vision, examining the oral cavity and dermatological lesions, providing a holistic view of the individual. Multidisciplinary interaction is desirable to improve the impact of these diseases on the QoL of individuals with psoriatic disease and PE.

Conclusion

This study demonstrated the negative impacts of PE on the OHRQoL of the analyzed individuals, being PSO, mainly PsA and PE individuals presenting significantly worse OHRQoL indicators.